4D MOLECULAR THERAPEUTICS INC (FDMT)
Health Care · Genetic medicine / gene therapy · NASDAQ
4D Molecular Therapeutics is a clinical-stage biotechnology company pioneering targeted genetic medicines to transform the treatment of debilitating ophthalmological and pulmonary diseases.
What 4D MOLECULAR THERAPEUTICS INC does
4D Molecular Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines for ophthalmology, pulmonology, and cardiology. Its primary lead candidate, 4D-150, uses a proprietary AAV vector to deliver anti-VEGF biologics to treat large-market retinal vascular diseases like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company also maintains a pipeline of gene therapy programs for conditions including geographic atrophy, cystic fibrosis, and alpha-1-antitrypsin deficiency.
Recent developments
In Q2 2026, the company completed enrollment for the 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD and secured a $200 million strategic credit facility with Hercules Capital. Additionally, the company announced it plans to initiate a Phase 3 clinical trial for 4D-150 in DME in the third quarter of 2026.
From 4D MOLECULAR THERAPEUTICS INC's filing of 2026-08-13.
Themes: gene therapy, ophthalmology / retinal disease, wet AMD / DME, pulmonary medicine / cystic fibrosis, precision medicine
Fundamentals
- Price$12.70 as of 2026-10-08 close
- Market cap$632M as of 2024-02-23 (share count; price 2026-10-08)
- 1-year return+31.5% 2025-10-08 close $9.66 → 2026-10-08 close $12.70
- P/En/a negative earnings
- Net margin-164.4% FY2025, SEC XBRL
- ROE-27.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue CAGR (3y)+200.9% SEC XBRL
- Beta1.18 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How FDMT compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How 4D MOLECULAR THERAPEUTICS INC looks technically
4D MOLECULAR THERAPEUTICS INC (FDMT) is trading 20.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 279 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 25.0% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 20.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +20.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.62 | $13.62 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.51 | $10.51 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 279 trading days ago — a "golden cross", a bullish long-term signal | 279 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 17.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($12.12 to $16.23) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 14.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.93 | $16.93 |
|---|---|---|
| From the 52-week high | it is 25.0% below its 52-week high (its highest price of the past year) | -25.0% |
| Above the 52-week low | it is 82.5% above its 52-week low (its lowest price of the past year) | +82.5% |
| Below the 52-week high | it is 25.0% below its highest point of the past year | 25.0% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $54.98 (set on 2021-03-10) | $54.98 |
| Given back of the 52-week move | over the past year its closes ranged ($7.19 to $16.76), and it has given back roughly a third of its rise from last year’s low — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.54 to $10.85. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 42.4% |
| From the all-time high | it is 76.9% below its all-time high | -76.9% |
| Nearest price level | it is trading 6.4% above a support level at $11.89 — a price it turned at three times since 2025-11-28, most recently on 2026-07-21. Since 2024-10-08 it has 14 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.4% |
| All-time low | its lowest closing price on record is $2.23 (set on 2025-04-09) | $2.23 |
| Above the all-time low | it is 468.2% above its all-time low | +468.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 48th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9005 between its high and its low — about 7.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9005 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.20 and $15.92 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.20 – $14.06 – $15.92 |
| Typical daily range (% of price) | its price moves about 7.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.1% |
| Stretch from the 200-day average | it is trading 2.4 daily ranges above its 200-day average price (20.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.99× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.3% since the prior reading | -0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.4% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.11% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 14.2 percentage points (the stock lost 13.2% while the market gained 1.0%) | -14.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 6.3 percentage points (the stock lost 2.5% while the market gained 3.8%) | -6.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 10.3 percentage points (the stock gained 27.8% while the market gained 17.5%) | +10.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.5 percentage points (the stock gained 31.5% while the market gained 15.0%) | +16.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.08 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +14.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $14.51 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -12.4% |
Price levels it has turned at before
FDMT last closed at $12.70 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.89 | Support | 6.4% below the last close | turned there three times · 2025-11-28 to 2026-07-21 |
| $13.61 | Resistance | 7.2% above the last close | turned there twice · 2026-08-31 to 2026-09-24 |
| $10.72 | Support | 15.6% below the last close | turned there twice · 2026-03-26 to 2026-04-17 |
| $9.81 | Support | 22.7% below the last close | turned there four times · 2025-11-10 to 2026-02-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$28.09 range $18.00 – $37.00; median $28.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FDMT
- Consensus EPS estimate-$1.05 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.00709 from -$1.04, on 2026-09-03, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in late-stage clinical development with no approved products and has a history of significant operating losses.","The business requires substantial additional capital to fund operations, and there is no guarantee that necessary financing will be available on favorable terms, if at all.","Development of genetic medicines is highly uncertain and subject to potential failure or delays in clinical trials and regulatory approval processes."]
What changed in the latest 10-Q
AI-assisted comparison of FDMT's 10-Q filed 2026-08-13 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states 4FRONT-1 overenrolled and 523 patients randomized, while older filing stated overenrolled and expected to exceed 500 patients randomized.
- Newer filing states topline data for 4FRONT-1 anticipated in the second quarter of 2027, while older filing stated first half of 2027.
- Newer filing states enrollment for 4FRONT-2 completed in June 2026 ahead of schedule with >500 patients expected to be randomized, while older filing stated enrollment expected to complete in the second half of 2026.
- Newer filing added July 2026 announcement of positive long-term results from the 4D-150 PRISM Phase 1/2 clinical trial in wet AMD.
- Newer filing states PRISM results with 2 years of follow-up, while older filing stated 1.5 to 2 years of follow-up.
- Newer filing states PRISM no new cases of intraocular inflammation reported with up to approximately 4 years of follow-up, while older filing stated up to approximately 3.5 years.
- Newer filing added that Otsuka Territory includes Korea.
- Newer filing added six months ended June 30, 2026 and 2025 net losses of $141.7 million and $102.6 million, respectively.
- Newer filing added accumulated deficit of $858.0 million as of June 30, 2026.
- Newer filing added mention of borrowings under loan facility with Hercules Capital, Inc. as a funding source.
- Removed:
- Older filing described 4D-150 as a safe, in-office, and durable lifelong backbone therapy; newer filing describes it as a routine in-office lifelong backbone therapy, removing the word 'safe' from that phrase.
- Older filing stated 4FRONT-2 was initiated in June 2025 and is enrolling both treatment-naïve and recently diagnosed, treatment-experienced patients; newer filing omits the specific initiation month and enrollment detail.
- Older filing stated net losses of $68.8 million and $48.0 million for the three months ended March 31, 2026 and 2025, respectively; newer filing contains three months ended June 30, 2026 and 2025 figures instead.
- Older filing stated accumulated deficit of $785.1 million as of March 31, 2026; newer filing contains June 30, 2026 figure instead.
- Reworded:
- Older filing referred to the agreement as 'Otsuka Collaboration and License Agreement'; newer filing refers to it as 'the Otsuka Agreement'.
- Older filing described 4D-710 for CF lung disease and 4D-725 for A1AT lung disease; newer filing describes 4D-710 for cystic fibrosis ('CF') lung disease and 4D-725 for alpha-1-antitrypsin deficiency ('AATD') lung disease.
- Older filing stated funding operations primarily through sale and issuance of equity securities and to a lesser extent from cash received pursuant to collaboration and license agreements; newer filing states funded primarily through sale and issuance of equity securities, from borrowings under loan facility with Hercules Capital, Inc. and, to a lesser extent, from cash received pursuant to collaboration and license agreements.
- Older filing stated 'We do not have any products approved for sale and have not generated any revenue from product sales since our inception...' and truncated; newer filing text available truncates earlier with 'We do not have any products approve' at the end of the excerpt.
- Notes:
- Newer filing excerpt appears truncated at 'We do not have any products approve', limiting comparison of the final paragraph.
- Older filing excerpt appears truncated at 'We will r', limiting comparison of the final paragraph.
- Some changes in wording could reflect the different reporting periods (Q1 vs Q2) rather than updates to the text itself.
Risk Factors
- Added:
- Newer filing (2026-08-13) includes net loss figures for the three months ended June 30, 2026 and 2025 ($72.9 million and $54.7 million) and six months ended June 30, 2026 and 2025 ($141.7 million and $102.6 million).
- Newer filing (2026-08-13) states accumulated deficit of $858.0 million as of June 30, 2026.
- Removed:
- Older filing (2026-05-07) included net loss figures for the three months ended March 31, 2026 and 2025 ($68.8 million and $48.0 million).
- Older filing (2026-05-07) stated accumulated deficit of $785.1 million as of March 31, 2026.
- Reworded:
- Newer filing (2026-08-13) states cash and cash equivalents and marketable securities of $430.6 million as of June 30, 2026; older filing (2026-05-07) stated $457.6 million as of March 31, 2026.
- Notes:
- The provided newer filing text is truncated mid-sentence at 'Additional funds may not be available when we need them, on t', so changes after that point could not be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 11 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 4 sells ($2M) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 11 sells ($3M) — 2 selling insiders
- Last 180 days · read to 2026-10-040 buys · 18 sells ($5M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-05. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about FDMT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FDMT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,002,451
- Reported value $133,032,590
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about FDMT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
FDMT had 12,008,645 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for FDMT because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 12,008,645
- Prior settlement (shares) 12,069,229
- Reported change -0.5%
- Days to cover (reported) 18.55
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron (REGN)
- Roche (RHHBY)
- Bayer (BAYRY)
- Novartis (NVS)
- Beam Therapeutics (BEAM)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FDMT vs…
4D MOLECULAR THERAPEUTICS INC is found in…
FDMT ranks in…
Frequently asked questions
What does 4D MOLECULAR THERAPEUTICS INC (FDMT) do?
4D Molecular Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines for ophthalmology, pulmonology, and cardiology. Its primary lead candidate, 4D-150, uses a proprietary AAV vector to deliver anti-VEGF biologics to treat large-market retinal vascular diseases like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
What sector is 4D MOLECULAR THERAPEUTICS INC (FDMT) in?
4D MOLECULAR THERAPEUTICS INC (FDMT) is classified in the Health Care sector. Its industry is Genetic medicine / gene therapy. It trades on NASDAQ.
Who are 4D MOLECULAR THERAPEUTICS INC's (FDMT) competitors?
Notable peers of 4D MOLECULAR THERAPEUTICS INC (FDMT) include Regeneron, Roche, Bayer, Novartis and Beam Therapeutics. This peer set is informational only — not financial advice.
Is 4D MOLECULAR THERAPEUTICS INC (FDMT) overbought or oversold right now?
4D MOLECULAR THERAPEUTICS INC (FDMT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FDMT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.